Opus Genetics Q2 revenue falls and misses estimates
IRD•Outlook
- Opus Genetics expects OPGx-BEST1 Cohort 1 topline data in the second week of September 2026
- Company expects dosing in the OPGx-LCA5 registrational trial to begin in Q4 2026
- Opus Genetics projects cash runway to fund operations into 2029
Overview
- U.S. gene therapy developer's Q2 revenue fell and missed analyst expectations
- Net loss widened from prior year, driven by higher R&D expenses and lower revenue
- Company expects cash runway to support operations into 2029
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Miss | $755,000 | $2.47 mln (17 Analysts) |
| Q2 Net Loss | $8.10 mln | ||
| Q2 Operating Expenses | $17.24 mln | ||
| Q2 Operating Income | -$16.48 mln | ||
| Q2 Pretax Loss | $8.10 mln |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the pharmaceuticals peer group is "buy".
Wall Street's median 12-month price target for Opus Genetics Inc is $10.00, about 164.6% above its August 5 closing price of $3.78.
